Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
复制标题
DOI：
10.1037/a0032707
复制
发表时间：
2013-07
期刊：
影响因子：
2.4
通讯作者：
Aisen, Paul S.
中科院分区：
文献类型：
--
作者：
Salmon, David P.;Ferris, Steven H.;Thomas, Ronald G.;Sano, Mary;Cummings, Jeffery L.;Sperling, Reisa A.;Petersen, Ronald C.;Aisen, Paul S.
在阿尔茨海默病合作研究进行的一项模拟阿尔茨海默病(AD)一级预防治疗试验中，这项研究考察了年龄和载脂蛋白E(APOE)基因对非痴呆老年参与者认知功能减退率的影响。在基线和随后的四次年度评估中，对417名年龄在74岁到93岁之间的非痴呆参与者(172名男性，245名女性)进行了认知测试(平均值=79.13±3.34)。286名参与者接受了APOE基因分型。四年来，在定向力、记忆力、执行功能和语言方面的指标明显下降。即使在控制了教育、性别、种族以及基线功能和认知能力后，APOEε4+(AD的一个遗传风险因素；n=73)的下降速度明显快于ε4−参与者(n=213)。这种差异随着年龄的增长而增加，这表明存在年龄X基因交互作用。这些结果与基于人群的研究一致，并将研究结果扩展到经过仔细筛选的样本，该样本符合AD初级预防试验的纳入和排除标准。年龄和载脂蛋白E基因在下降速度上的交互作用表明，临床前疾病可能在ε4+以上的老年个体中出现过多。因此，在设计AD一级预防治疗试验时，应考虑载脂蛋白E基因和年龄。
This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in non-demented elderly participants in a simulated Alzheimer’s disease (AD) primary prevention treatment trial carried out by the Alzheimer’s Disease Cooperative Study. Cognitive tests were administered at baseline and at four subsequent annual evaluations to 417 non-demented participants (172 men, 245 women) between the ages of 74 and 93 (mean=79.13 ± 3.34). APOE genotyping was available for 286 of the participants. Four-year decline was evident on measures of orientation, memory, executive function and language. Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n=73) than ε4− participants (n=213), even after controlling for education, gender, ethnicity, and baseline functional and cognitive abilities. This discrepancy increased with increasing age indicating an age X genotype interaction. These results are consistent with population-based studies, and extend the findings to a carefully-screened sample that meets inclusion and exclusion criteria for an AD primary prevention trial. The interaction between age and APOE genotype on rate of decline suggests that preclinical disease may be over represented in olderε4+ individuals. Thus, APOE genotype and age should be considered in the design of AD primary prevention treatment trials.
登录
查看更多内容
影响因子：
2.4
作者：
Nilsson, Lars-Goran;Adolfsson, Rolf;Van Broeckhoven, Christine
通讯作者：
Van Broeckhoven, Christine
影响因子：
9.9
作者：
Salmon, DP;Thomas, RG;Katzman, R
通讯作者：
Katzman, R
影响因子：
3.7
作者：
Small, BJ;Basun, H;Backman, L
通讯作者：
Backman, L
影响因子：
3.7
作者：
Bondi, MW;Salmon, DP;Thal, LJ
通讯作者：
Thal, LJ
DOI：
10.1097/01.wad.0000213870.40300.21
发表时间：
2006-10-01
影响因子：
2.1
作者：
Ferris, Steven H.;Aisen, Paul S.;Thal, Leon J.
通讯作者：
Thal, Leon J.